Orbus Therapeutics Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $10M

  • Investors
  • 6

Orbus Therapeutics General Information

Description

Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The company's products are irreversible inhibitors of ornithine decarboxylase (ODC) that delay or freeze tumor growth by inhibiting the production of the enzyme, enabling medical professionals to prevent tumor growth in certain types of cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • 2479 East Bayshore Road
  • Suite 105
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Orbus Therapeutics Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orbus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 11-Aug-2020 $10M 0000 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A3) 000 0000 0000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A2) 20-Mar-2019 $18.5M $51M 000.00 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 19-Aug-2015 $32.5M $32.5M 000.00 Completed Clinical Trials - Phase 3
To view Orbus Therapeutics’s complete valuation and funding history, request access »

Orbus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-4 00,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-3 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 26,452,884 $0.010000 $1.01 $1.01 1x $1.01 31.5%
Series A 21,428,577 $0.010000 $0.84 $0.84 1x $0.84 25.52%
To view Orbus Therapeutics’s complete cap table history, request access »

Orbus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The
Drug Discovery
Palo Alto, CA
9 As of 2017
0000
0000 0000-00-00
00000000000 0000

000000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000000000000
Holliston, MA
00 As of 0000
000.00
000000000 000.00

000000

it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna ali
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orbus Therapeutics Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Perthera Private Equity-Backed Holliston, MA 00 000.00 000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00 000000 Venture Capital-Backed Basel, Switzerland 00 000.00 0000000000 0 000.00
00000000 000000000 Formerly VC-backed Houston, TX 00 00000 000000000 00000
You’re viewing 5 of 44 competitors. Get the full list »

Orbus Therapeutics Patents

Orbus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3523274-A1 Formulations for administration of eflornithine Pending 06-Oct-2016 0000000000
EP-3523274-A4 Formulations for administration of eflornithine Pending 06-Oct-2016 0000000000
AU-2017339781-A1 Formulations for administration of eflornithine Active 06-Oct-2016 0000000000
AU-2017339781-B2 Formulations for administration of eflornithine Active 06-Oct-2016 000000000 0
CA-3038530-A1 Formulations for administration of eflornithine Pending 06-Oct-2016 A61K31/197
To view Orbus Therapeutics’s complete patent history, request access »

Orbus Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Myers Co-Founder, President, Chief Executive Officer & Board Member
Victor Levin Co-Founder and Medical Advisor
Jason Levin Co-Founder, Board Member & Chief Operating Officer
To view Orbus Therapeutics’s complete executive team members history, request access »

Orbus Therapeutics Board Members (9)

Name Representing Role Since
Alex Zisson Self Board Member 000 0000
Ernest Mario Ph.D Self Chairman 000 0000
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
Jason Levin Orbus Therapeutics Co-Founder, Board Member & Chief Operating Officer 000 0000
Kurt Emster Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Orbus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orbus Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Agent Capital Venture Capital Minority 000 0000 000000 0
Adams Street Partners PE/Buyout Minority 000 0000 000000 0
Ernest Mario Angel (individual) Minority 000 0000 000000 0
H.I.G. BioHealth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »